EMEA-001773-PIP01-15
Key facts
| Active substance |
DNA, d(P-thio)([2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rC-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]rG-G-T-T-A-m5C-A-T-G-A-A-[2'-0-(2-methoxyethyl)]rA-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rC-[2'-0-(2-methoxyethy l)]m5rC-[2'-0-(2-methoxyethyl)]m5rC), sodium salt
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0181/2015
|
| PIP number |
EMEA-001773-PIP01-15
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of transthyretin-related amyloidosis (ATTR amyloidosis)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Isis Pharmaceuticals, Inc.
Email: info@akceatx.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|